Expert Interview
A Second Look: Reviewing commercial options for PAH, including Tyvaso, Yutrepia and Winrevair
Ticker(s): LQDA, UTHR, MRKInstitution: Somerset Pulmonology
- Pulmonologist at private practice and Associate Professor at Robert Wood Johnson Medical School
- Oversees 230 PAH patients
- World-renowned expertise in treating patients with pulmonary hypertension and interstitial lung disease
In which patients are you prescribing Yutrepia?
Added By: slingshot_insightsComparing the 3 options of Tyvaso, Yutrepia and Winrevair, do you have a preference?
Added By: slingshot_insightsAre there any investigational therapies in PAH you are interested in?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
